Omega Bio-tek, a leading provider of nucleic acid purification solutions, has announced the completion of a significant expansion of its Research and Development facility at its Oakbrook location, increasing the company’s R&D footprint by approximately 50% and reinforcing its ongoing investment in scientific innovation, product development, and collaboration.
The expanded facility is designed to enhance Omega Bio-tek’s ability to develop next-generation DNA and RNA purification technologies that support genomics, molecular biology, clinical research and other life sciences applications. The additional space provides increased capacity for application development, workflow optimisation, product testing, and cross-functional collaboration among scientific, engineering, and technical support teams.
A key feature of the expansion is a dedicated automation demonstration laboratory, where visitors can evaluate automated sample preparation workflows using their own samples and protocols. Working alongside Omega Bio-tek’s scientific and technical specialists, customers can assess workflow performance, optimise protocols, and gain confidence before implementing automation solutions within their own laboratories.
The investment reflects Omega Bio-tek’s continued commitment to scientific innovation and customer-focused product development. It is designed to support both current product lines and future technologies that address evolving needs in life sciences discovery, clinical research, biobanking, genomics and laboratory automation.
Completed in June 2026, the Oakbrook R&D expansion represents another milestone in Omega Bio-tek’s long-term commitment to advancing sample preparation technologies and providing researchers with scientific expertise, innovative products, and practical support needed to accelerate discovery and improve laboratory efficiency.
